investorscraft@gmail.com

Intrinsic value of Surmodics, Inc. (SRDX)

Previous Close$33.80
Intrinsic Value
Upside potential
Previous Close
$33.80

VALUATION INPUT DATA (original, your and others' valuations)

ParameterOrig.Your
Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh12.88 

The original valuation is based on fiscal year data as of 2021-09-30 and quarterly data as of 2022-03-31.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment designs, develops, and manufactures interventional medical devices primarily for the peripheral vascular market; and offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets. The Vitro Diagnostics segment provides stabilization products, substrates, antigens, and surface coatings to diagnostics customers; and manufactures or sells components for in vitro diagnostic immunoassay and molecular tests, as well as surface coatings to the diagnostic, biomedical research, and life science markets. Surmodics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2021(a)2022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046

INCOME STATEMENT

Revenue growth rate, %10.8NaN
Revenue, $105NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m98NaN
Operating income, $m7NaN
EBITDA, $m15NaN
Interest expense (income), $mNaN
Earnings before tax, $m6NaN
Tax expense, $m2NaN
Net income, $m4NaN

BALANCE SHEET

Cash and short-term investments, $m39NaN
Total assets, $m195NaN
Adjusted assets (=assets-cash), $m156NaN
Average production assets, $m94NaN
Working capital, $m40NaN
Total debt, $m14NaN
Total liabilities, $m55NaN
Total equity, $m140NaN
Debt-to-equity ratio0.098NaN
Adjusted equity ratio0.718NaN

CASH FLOW

Net income, $m4NaN
Depreciation, amort., depletion, $m8NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m15NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-5NaN
Free cash flow, $m21NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m40
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount